Getting started

Getting started with Minivelle®

Getting Started

Multiple dosing options to fit your treatment needs

Minivelle® (estradiol transdermal system) for the treatment of menopause-related moderate to severe hot flashes and night sweats and the prevention of postmenopausal osteoporosis comes in 5 dosage strengths so you and your doctor can find the one that may be right for you. Minivelle® 0.025 mg/day is indicated for the prevention of postmenopausal osteoporosis only.

If you use Minivelle only to prevent osteoporosis from menopause, talk to your healthcare provider about whether a different treatment or medicine without estrogens might be better for you.

Hormone patch Minivelle for treatment of hot flashes and night sweats in menopause. Also FDA approved for prevention of postmenopausal osteoporosis.

Doctors are likely to start you on the lowest effective dose of estrogen. You and your doctor should talk regularly (for example, every 3 to 6 months) about the dose you are using and whether you still need treatment with Minivelle®.

Switching to Minivelle®

If you are currently on Vivelle-Dot® for the treatment of moderate to severe hot flashes and night sweats, your doctor can decide if it's right to switch you from your current Vivelle-Dot® dose to the same Minivelle® dose.

Talk to your doctor because you may even be able to start using Minivelle® the next time you switch your patch!

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about MINIVELLE® (an estrogen hormone)?

  • Using estrogen-alone may increase your chance of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are using MINIVELLE® as vaginal bleeding after menopause may be a warning sign of cancer of the uterus. Your healthcare provider should check any unusual vaginal bleeding to find out the cause.

  • Do not use estrogen-alone or estrogen with progestins to prevent heart disease, heart attacks, strokes, or dementia (decline in brain function).

  • Using estrogen-alone may increase your chances of getting strokes or blood clots, while using estrogens with progestins may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots.

  • Using estrogen-alone or estrogen with progestins may increase your chance of getting dementia, based on a study of women 65 years of age or older.

  • You and your healthcare provider should talk regularly about whether you still need treatment with MINIVELLE®.

MINIVELLE® should not be used if you have unusual vaginal bleeding, currently have or have had certain cancers, had a stroke or heart attack, currently have or have had blood clots, currently have or have had liver problems, have been diagnosed with a bleeding disorder, are allergic to MINIVELLE® or any of its ingredients, or think you may be pregnant.

Before you take MINIVELLE®, tell your healthcare provider if you have unusual vaginal bleeding, have any other medical conditions, are going to have surgery or will be on bed rest, are breast feeding, and about all of the medicines you take.

The most common side effects that may occur with MINIVELLE® are headache, breast tenderness, back and limb pain, common cold, upset stomach, nausea, inflammation of the sinuses and irregular vaginal bleeding or spotting.

MINIVELLE® should be used at the lowest effective dose and for the shortest duration consistent with your treatment goals and risks.

These are not all the possible side effects of MINIVELLE®. Please read the Patient Information section within the full Prescribing Information before taking MINIVELLE®. For more information ask your healthcare provider or pharmacist for advice about side effects.

INDICATION

MINIVELLE® (estradiol transdermal system) is a prescription medicine patch that contains estradiol (an estrogen hormone). MINIVELLE® is used to reduce moderate to severe hot flashes due to menopause and to help prevent postmenopausal osteoporosis (thin weak bones). The 0.025 mg/day dose is only approved for the prevention of postmenopausal osteoporosis.

If you use MINIVELLE® only to prevent osteoporosis from menopause, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you.

Click here for the full Prescribing Information, including Boxed WARNING.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.


DOT Matrix™ is a trademark of Noven Pharmaceuticals, Inc.

Minivelle® and the Minivelle Logo are trademarks of Noven Therapeutics, LLC.

Vivelle-Dot® is a registered trademark of Novartis AG.

For information, call 1-800-455-8070.

©2017 Noven Therapeutics, LLC. All rights reserved. For U.S. Audience Only. MINI-3503-16 1/17

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about MINIVELLE® (an estrogen hormone)?

  • Using estrogen-alone may increase your chance of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are using MINIVELLE® as vaginal bleeding after menopause may be a warning sign of cancer of the uterus. Your healthcare provider should check any unusual vaginal bleeding to find out the cause.

  • Do not use estrogen-alone or estrogen with progestins to prevent heart disease, heart attacks, strokes, or dementia (decline in brain function).

  • Using estrogen-alone may increase your chances of getting strokes or blood clots, while using estrogens with progestins may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots.

  • Using estrogen-alone or estrogen with progestins may increase your chance of getting dementia, based on a study of women 65 years of age or older.

  • You and your healthcare provider should talk regularly about whether you still need treatment with MINIVELLE®.

MINIVELLE® should not be used if you have unusual vaginal bleeding, currently have or have had certain cancers, had a stroke or heart attack, currently have or have had blood clots, currently have or have had liver problems, have been diagnosed with a bleeding disorder, are allergic to MINIVELLE® or any of its ingredients, or think you may be pregnant.

Before you take MINIVELLE®, tell your healthcare provider if you have unusual vaginal bleeding, have any other medical conditions, are going to have surgery or will be on bed rest, are breast feeding, and about all of the medicines you take.

The most common side effects that may occur with MINIVELLE® are headache, breast tenderness, back and limb pain, common cold, upset stomach, nausea, inflammation of the sinuses and irregular vaginal bleeding or spotting.

MINIVELLE® should be used at the lowest effective dose and for the shortest duration consistent with your treatment goals and risks.

These are not all the possible side effects of MINIVELLE®. Please read the Patient Information section within the full Prescribing Information before taking MINIVELLE®. For more information ask your healthcare provider or pharmacist for advice about side effects.

INDICATION

MINIVELLE® (estradiol transdermal system) is a prescription medicine patch that contains estradiol (an estrogen hormone). MINIVELLE® is used to reduce moderate to severe hot flashes due to menopause and to help prevent postmenopausal osteoporosis (thin weak bones). The 0.025 mg/day dose is only approved for the prevention of postmenopausal osteoporosis.

If you use MINIVELLE® only to prevent osteoporosis from menopause, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you.

Click here for the full Prescribing Information, including Boxed WARNING.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.